Derivative polypeptide PM6 and application thereof in antithrombosis

By intercepting the polypeptide from the transcriptome of the phenanthirs salivary glands and combining the {d-Phe}-PRP fragment to form the derived polypeptide PM6, the problem of high bleeding risk for existing anticoagulants is solved, and effective antithrombotic effects and low bleeding risk is achieved.

CN119684441AActive Publication Date: 2025-03-25KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
3 Cites 0 Cited by

Patent Information

Application Number
CN202510003366.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-02
Publication Date
2025-03-25
Estimated Expiration
2045-01-02

AI Technical Summary

Technical Problem

Existing anticoagulants such as hirudin have a risk of bleeding in clinical applications, limiting their widespread use, and it is difficult to find alternatives to effectively inhibit thrombosis and have a low risk of bleeding.

Method used

By obtaining the original polypeptide from the transcriptome of the phenanthirs salivary glands and intercepting some of the peptides on it, binding to the {d-Phe}-PRP fragment, the derived polypeptide PM6 is formed by connecting the polypeptide, which has a significant antithrombotic effect and a low risk of bleeding.

Benefits of technology

The derived polypeptide PM6 significantly inhibits thrombin activity and has good antithrombotic effects. Its bleeding risk is comparable to that of the positive drug Biluvadine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of polypeptide synthesis and biological medicine, and particularly relates to a derived polypeptide PM6 and application thereof in antithrombosis. An original polypeptide SEQ ID NO: 1 is obtained from a transcriptome of salivary glands of poecilobdella manillensis, a truncated polypeptide shown as SEQ ID NO: 3 is obtained from the original polypeptide, and on the basis, {d-Phe}-PRP is added at the N end of the intercepted amino acid sequence through a synthesis strategy of a hirudin analogue Bivalirudin medicine, so that the hirudin analogue is obtained. And connecting {d-Phe}-PRP with the truncated polypeptide through a connecting polypeptide to obtain the derivative polypeptide PM6. The derivative polypeptide PM6 has a good antithrombotic effect, and the bleeding risk of the derivative polypeptide PM6 is equivalent to that of a positive drug, namely, ruvapine.
Need to check novelty before this filing date? Find Prior Art